NEW YORK — Chinese diagnostics firm New Horizon Health has gone public on the Hong Kong Stock Exchange, venture capital firm Qiming Venture Partners said on Thursday.
New Horizon, one of Qiming's portfolio companies, focuses on tests for early cancer screening tests and offers two fecal immunochemical tests approved in China: ColoClear for individuals at high-risk for colorectal cancer and Pupu Tube for general colorectal cancer screening.
The company is also developing a stool-based gastric cancer screening test called UU Tube and a urine-based cervical cancer screen called CerviClear, according to Qiming.
Qiming said that New Horizon's shares went public at HK$26.66 (US$3.44).
In late 2019, New Horizon partnered with Prenetics to offer ColoClear in Hong Kong and certain other Asian markets.